# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sigmund Freud (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET005-SYN-TD
- Date: 1930-08-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anton Reinholt, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Twelve-week review: five weeks without smoking and the new obturator. **S**

## History of present illness

Mr. Freud returns twelve weeks after intake. He stopped smoking on his quit date five weeks ago. In the second week he smoked one cigar after a dinner with colleagues, felt worse for it, and has not smoked since; he did not treat it as a reason to give up. He uses the 21 mg patch each morning and three to five lozenges a day, and takes varenicline 1 mg twice daily. He sleeps well and his mood is steady. Dr. Vasquez-Lindqvist fitted the new obturator this morning, and with it there is no nasal leakage. He has had four speech-language therapy sessions since the last visit. His head and neck surgeon's yearly examination two weeks ago, with flexible endoscopy, found no recurrence and no second cancer. His pain is 3 of 10. **S**

| Element | Detail |
|---|---|
| Tobacco | No smoking for five weeks except one cigar in the second week |
| Treatment | Varenicline 1 mg twice daily; 21 mg patch; three to five lozenges a day |
| New obturator | Fitted this morning; no nasal leakage |
| Surveillance | Surgeon's yearly examination two weeks ago: no recurrence |
| Pain | 3 of 10 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight up; appetite better since stopping smoking |
| Ears, nose, mouth, and throat | Negative | No nasal leakage with the new obturator; no sore, lump or bleeding |
| Respiratory | Negative | Morning cough almost gone |
| Psychiatric | Negative | Mood steady; cravings brief and manageable |

4 systems reviewed. **S**

## Current medications

- Varenicline 1 mg oral tablet, one tablet twice daily after food; planned for at least 24 weeks **S**
- Nicotine 21 mg/24 hours transdermal patch, one patch each morning from the quit date, for six weeks **S**
- Nicotine 4 mg oral lozenge, one lozenge as needed for cravings, up to 10 a day, dissolved on the side away from the obturator; gum avoided because it sticks to the prosthesis **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain at the maxillectomy site **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 59.8 kg; BMI 20.2 kg/m². All vital signs are synthetic.

Albumin: 3.7 g/dL; Pain score (0 to 10): 3. All results are synthetic.

## Change since baseline

- Albumin: 3.4 g/dL (low) at baseline, 3.7 g/dL at this visit **S**
- Pain score (0 to 10): 6 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 132/78, pulse 70; weight 59.8 kg |
| Mouth | New obturator well seated; no pressure areas; mucosa healthy; no mass or white or red patch |
| Speech | Normal resonance with the obturator in |
| Skin | Mild redness at the last patch site only |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Tobacco use disorder, severe, in early remission** (F17.290). Five weeks without smoking after one slip that he handled well. Varenicline is continued beyond 12 weeks to lower the chance of relapse. **S**
   - Continue varenicline 1 mg twice daily for at least 24 weeks in total.
   - Step the patch down to 14 mg from next week for four weeks, then stop.
   - Continue lozenges as needed and quitline calls every two weeks.
2. **History of palatal squamous cell carcinoma** (Z85.818). No recurrence or second primary on the surgeon's yearly examination. **S**
   - Next surgeon's examination in one year; mouth checked at each visit here.
3. **Hypernasal speech and nasal leakage** (R49.21). Resolved with the new obturator and speech therapy. **S**
   - Two more speech-language therapy sessions to finish the course.
4. **Weight loss** (R63.4). Weight 59.8 kg and albumin 3.7 g/dL, both recovering. **S**
   - Continue supplements until weight is over 60 kg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Tobacco use (cigars a day), readiness and quit date | Every visit | Completed today | No smoking for five weeks except one cigar in the second week; exhaled carbon monoxide 4 ppm (narrative) |
| Medication safety | Varenicline adherence and side effects (nausea, sleep, dreams, mood) | Every visit; at least 12 weeks, extended to 24 weeks or more | Completed today | Taking it twice daily; no side effects now; extended to at least 24 weeks |
| Medication safety | Combination nicotine replacement (patch and lozenge) | From the quit date for at least 8 to 12 weeks | Completed today | 21 mg patch for six weeks, then 14 mg for four weeks; lozenges three to five a day; mild redness at patch sites |
| Self-management | Behavioral support (quitline and clinic sessions) | Weekly calls around the quit date, then every two to four weeks | Completed today | Weekly quitline calls around the quit date; now every two weeks |
| Self-management | Relapse prevention | Every visit | Completed today | The slip was reviewed without blame; plan for dinners and travel |
| Examination | Head and neck surveillance examination (mouth, defect and neck) | Yearly by his head and neck surgeon more than five years after treatment; mouth checked at each visit | Completed today | Surgeon's yearly examination with flexible endoscopy two weeks ago: no recurrence or second primary; mouth healthy today |
| Imaging | Head and neck imaging | Only for symptoms or signs more than five years after treatment | Not indicated | No symptoms or signs |
| Examination | Obturator fit, seal and hygiene | Every visit | Completed today | New definitive obturator fitted this morning by Dr. Vasquez-Lindqvist; good seal |
| Examination | Speech and swallowing (hypernasality, nasal leakage) | Every visit; speech-language therapy as needed | Completed today | Four therapy sessions since the corrective action; normal resonance with the new obturator |
| Examination | Weight and nutrition | Every visit | Completed today | 59.8 kg |
| Laboratory | Albumin | Baseline and at three months while weight is recovering | Completed today | Albumin 3.7 g/dL, from 3.4 |
| Survey | Pain score and function | Every visit | Completed today | 3 of 10, measured before the new obturator was fitted |
| Medication safety | Acetaminophen daily dose (no more than 3,000 mg) | Every visit | Completed today | 3,000 mg a day |
| Medication safety | Opioids | Avoid long-term opioids | Not indicated | Not needed |

## Goal progress

- Stop smoking cigars completely, at a pace he chooses, using varenicline and nicotine replacement. In progress; target 1930-10-26. **S**
- An obturator that seals and does not rub, so that speech is clear and liquids do not leak into his nose. Outcome by 1930-08-24: Reline at two weeks; new definitive obturator fitted at twelve weeks; speech clear and no nasal leakage. **S**
- Pain at 3 of 10 or less without opioids. In progress; target 1930-10-26. **S**
- Regain weight to at least 60 kg with a normal albumin. In progress; target 1930-10-26. **S**

## Guideline basis

- Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (Am J Respir Crit Care Med 2020;202(2):e5-e31)
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 2.2026 (follow-up and survivorship) (2026), National Comprehensive Cancer Network
- American Cancer Society Head and Neck Cancer Survivorship Care Guideline (2016), American Cancer Society (CA Cancer J Clin 2016;66(3):203-239)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)

## Follow-up

- Patch step-down from next week. Quitline every two weeks. Two more speech-language therapy sessions. Five-month review in nine weeks with blood count, albumin, kidney function and ALT. **S**
- Next scheduled visit 1930-09-28: subsequent annual wellness visit. **S**
